Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of S 38093 and donepezil in mild to moderate Alzheimer's disease
2009-012035-15Phase 2Completed
- Sponsor
- Servier
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of S-38093 in Alzheimer's disease (AD), sponsored by Servier. Primary endpoints: Safety of S 38093 in combination with donepezil and Efficacy after 4 weeks of co-administration. Started Jul 2009; status: completed.
02
Drugs
S-38093
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-012035-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012035-15.